Clinical Trials Browser

Phase 1/2 × Recruiting × Diffuse Intrinsic Pontine Glioma × Clear all

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT04870944 2026-05-05

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Phase 1/2 Recruiting

63 enrolled

CNSLymphoid

Diffuse Intrinsic Pontine Glioma, Lymphoma

NCT05278208 2026-04-13

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

Phase 1/2 Recruiting

65 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioma, Medulloblastoma, Meningioma, Neoplasms, Germ Cell and Embryonal, Central Nervous System Neoplasms

NCT07501156 2026-03-30

H3K27M-specific Immune Effector Cells Targeting DMG/DIPG

Phase 1/2 Recruiting

30 enrolled

CNS

Diffuse Intrinsic Pontine Glioma

NCT05956821 2025-12-08

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

Phase 1/2 Recruiting

20 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Oligodendroglioma

Clinical Trials

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

H3K27M-specific Immune Effector Cells Targeting DMG/DIPG

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age